RU2011143747A - DETECTION OF FIBRIN AND FIBRINOGEN DECOMPOSITION PRODUCTS AND RELATED METHODS FOR PRODUCING AND USING FOR DETECTING AND MONITORING CANCER - Google Patents

DETECTION OF FIBRIN AND FIBRINOGEN DECOMPOSITION PRODUCTS AND RELATED METHODS FOR PRODUCING AND USING FOR DETECTING AND MONITORING CANCER Download PDF

Info

Publication number
RU2011143747A
RU2011143747A RU2011143747/15A RU2011143747A RU2011143747A RU 2011143747 A RU2011143747 A RU 2011143747A RU 2011143747/15 A RU2011143747/15 A RU 2011143747/15A RU 2011143747 A RU2011143747 A RU 2011143747A RU 2011143747 A RU2011143747 A RU 2011143747A
Authority
RU
Russia
Prior art keywords
fdp
fragment
antibody
antibody preparation
cancer
Prior art date
Application number
RU2011143747/15A
Other languages
Russian (ru)
Inventor
Андреа СМОЛЛ-ХОВАРД
Original Assignee
ЭйЭмДиЭл, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ЭйЭмДиЭл, ИНК. filed Critical ЭйЭмДиЭл, ИНК.
Publication of RU2011143747A publication Critical patent/RU2011143747A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/75—Fibrin; Fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

1. Способ обнаружения рака у индивидуума, включающий стадии:взятия биологического образца у указанного индивидуума;взаимодействия указанного биологического образца с препаратом антител, который связывается по меньшей мере с тремя антигенами, ассоциированными с продуктами разложения фибрина и фибриногена (FDP) с образованием комплексов антитело-FDP, где указанными тремя FDP-ассоциированными антигенами являются фрагмент D, фрагмент Е и D-димер;детектирования указанных комплексов антитело-FDP идиагностики рака у указанного индивидуума.2. Способ по п.1, в котором указанный препарат антител дополнительно необязательно связывается, по меньшей мере с одним из фрагмента Y и исходных продуктов расщепления плазмином (IPDP).3. Способ по п.1, в котором указанным препаратом антител является препарат поликлонального антитела.4. Способ по п.1, включающий твердофазный иммуноферментный анализ.5. Способ по п.1, в котором стадия диагностики дополнительно включает по меньшей мере один дополнительный диагностическый тест.6. Способ мониторинга рака у пациента, включающий:(a) взятие первого биологического образца у указанного индивидуума, где первый образец отбирают в первый момент времени для взятия образца;(b) взятие второго биологического образца у указанного индивидуума, где указанный второй образец отбирают во второй момент времени для взятия образца после первого момента времени для взятия образца;(c) взаимодействия указанных биологических образцов с препаратом антител, который связывается по меньшей мере с тремя антигенами, ассоциированными с FDP, с образованием комплексов антитело-FDP, где указанными тремя FDP-ассоциированными антиг1. A method for detecting cancer in an individual, comprising the steps of: taking a biological sample from said individual; interaction of said biological sample with an antibody preparation that binds to at least three antigens associated with fibrin and fibrinogen degradation products (FDP) with the formation of antibody- FDP, wherein said three FDP-associated antigens are fragment D, fragment E and D-dimer; detecting said antibody-FDP complexes and diagnosing cancer in said individual. 2. The method of claim 1, wherein said antibody preparation further optionally binds to at least one of the Y fragment and the initial plasmin cleavage products (IPDP). The method of claim 1, wherein said antibody preparation is a polyclonal antibody preparation. The method according to claim 1, comprising an enzyme-linked immunosorbent assay. The method of claim 1, wherein the diagnostic step further comprises at least one additional diagnostic test. A method for monitoring cancer in a patient, comprising: (a) taking a first biological sample from said individual, where the first sample is taken at a first time point for sampling; (b) taking a second biological sample from said individual, where said second sample is taken at a second time time for sampling after the first time point for sampling; (c) the interaction of these biological samples with an antibody preparation that binds to at least three antigens associated with FDP, to form complexes of antibody-FDP, where the specified three FDP-associated antigens

Claims (15)

1. Способ обнаружения рака у индивидуума, включающий стадии:1. A method for detecting cancer in an individual, comprising the steps of: взятия биологического образца у указанного индивидуума;taking a biological sample from said individual; взаимодействия указанного биологического образца с препаратом антител, который связывается по меньшей мере с тремя антигенами, ассоциированными с продуктами разложения фибрина и фибриногена (FDP) с образованием комплексов антитело-FDP, где указанными тремя FDP-ассоциированными антигенами являются фрагмент D, фрагмент Е и D-димер;the interaction of the specified biological sample with an antibody preparation that binds to at least three antigens associated with the decomposition products of fibrin and fibrinogen (FDP) with the formation of antibody-FDP complexes, where these three FDP-associated antigens are fragment D, fragment E and D- dimer; детектирования указанных комплексов антитело-FDP иdetecting said antibody-FDP complexes and диагностики рака у указанного индивидуума.diagnosis of cancer in the specified individual. 2. Способ по п.1, в котором указанный препарат антител дополнительно необязательно связывается, по меньшей мере с одним из фрагмента Y и исходных продуктов расщепления плазмином (IPDP).2. The method of claim 1, wherein said antibody preparation further optionally binds to at least one of Y fragment and plasmin cleavage starting products (IPDP). 3. Способ по п.1, в котором указанным препаратом антител является препарат поликлонального антитела.3. The method according to claim 1, wherein said antibody preparation is a polyclonal antibody preparation. 4. Способ по п.1, включающий твердофазный иммуноферментный анализ.4. The method according to claim 1, including enzyme-linked immunosorbent assay. 5. Способ по п.1, в котором стадия диагностики дополнительно включает по меньшей мере один дополнительный диагностическый тест.5. The method according to claim 1, in which the stage of diagnosis further includes at least one additional diagnostic test. 6. Способ мониторинга рака у пациента, включающий:6. A method for monitoring cancer in a patient, comprising: (a) взятие первого биологического образца у указанного индивидуума, где первый образец отбирают в первый момент времени для взятия образца;(a) taking a first biological sample from said individual, where the first sample is taken at a first time point for sampling; (b) взятие второго биологического образца у указанного индивидуума, где указанный второй образец отбирают во второй момент времени для взятия образца после первого момента времени для взятия образца;(b) taking a second biological sample from said individual, wherein said second sample is taken at a second time point for taking a sample after the first time point for taking a sample; (c) взаимодействия указанных биологических образцов с препаратом антител, который связывается по меньшей мере с тремя антигенами, ассоциированными с FDP, с образованием комплексов антитело-FDP, где указанными тремя FDP-ассоциированными антигенами являются фрагмент D, фрагмент Е и D-димер;(c) the interaction of these biological samples with an antibody preparation that binds to at least three FDP-associated antigens to form antibody-FDP complexes, wherein said three FDP-associated antigens are fragment D, fragment E and D-dimer; (d) детектирование указанных комплексов антитело-FDP;(d) detecting said antibody-FDP complexes; (е) определение отношения уровня FDP в указанном втором биологическом образце к уровню FDP в первом биологическом образце;(e) determining the ratio of the FDP level in the specified second biological sample to the FDP level in the first biological sample; (f) определение прогрессирования рака и(f) determining the progression of cancer and необязательно повторение стадий (a)-(e) с дополнительными биологическими образцами, взятыми в момент времени после указанного первого и указанного второго момента времени.optionally repeating steps (a) to (e) with additional biological samples taken at a point in time after said first and said second point in time. 7. Способ по п.6, в котором указанный препарат антител необязательно дополнительно связывается по меньшей мере с одним из фрагмента Y и исходных продуктов расщепления плазмином (IPDP).7. The method of claim 6, wherein said antibody preparation optionally further binds to at least one of Y fragment and plasmin cleavage starting products (IPDP). 8. Способ по п.6, в котором указанным препаратом антител является препарат поликлонального антитела.8. The method according to claim 6, wherein said antibody preparation is a polyclonal antibody preparation. 9. Способ по п.6, в котором указанные реакции взаимодействия и детектирования включают твердофазный иммуноферментный анализ.9. The method according to claim 6, in which these reaction reactions and detection include enzyme-linked immunosorbent assay. 10. Способ по п.6, в котором указанный рак считается прогрессирующим, если указанное отношение больше или равно 1,15.10. The method according to claim 6, wherein said cancer is considered progressive if said ratio is greater than or equal to 1.15. 11. Способ по п.6, в котором указанный рак считается регрессирующим или является стабильным, если указанное отношение меньше 1,15.11. The method according to claim 6, in which the specified cancer is considered regressive or is stable if the specified ratio is less than 1.15. 12. Набор для обнаружения рака у индивидуума, включающий:12. A kit for detecting cancer in an individual, including: препарат антител, который связывается по меньшей мере с тремя антигенами, ассоциированными с FDP, где указанными тремя FDP-ассоциированными антигенами являются фрагмент D, фрагмент E и D-димер;an antibody preparation that binds to at least three FDP-associated antigens, wherein said three FDP-associated antigens are D fragment, E fragment and D-dimer; систему детектирования иdetection system and инструкции по измерению указанного FDP и корреляции присутствия указанного FDP с раковым заболеванием.instructions for measuring said FDP and correlating the presence of said FDP with cancer. 13. Набор по п.12, где указанная система детектирования включает антитело детекции, специфичное по меньшей мере к трем антигенам, ассоциированным с FDP, где указанными тремя FDP-ассоциированными антигенами являются фрагмент D, фрагмент E и D-димер.13. The kit of claim 12, wherein said detection system comprises a detection antibody specific for at least three FDP-associated antigens, wherein said three FDP-associated antigens are fragment D, fragment E, and D-dimer. 14. Набор по п.13, где указанный препарат антител необязательно дополнительно связывается по меньшей мере с одним из фрагмента Y и исходных продуктов расщепления плазмином (IPDP).14. The kit of claim 13, wherein said antibody preparation optionally further binds to at least one of Y fragment and plasmin cleavage starting products (IPDP). 15. Набор по п.12, где указанное антитело и указанная система детектирования включают твердофазный иммуноферментный анализ. 15. The kit according to item 12, where the specified antibody and the specified detection system include enzyme-linked immunosorbent assay.
RU2011143747/15A 2009-03-30 2009-03-30 DETECTION OF FIBRIN AND FIBRINOGEN DECOMPOSITION PRODUCTS AND RELATED METHODS FOR PRODUCING AND USING FOR DETECTING AND MONITORING CANCER RU2011143747A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2009/038833 WO2010114514A1 (en) 2009-03-30 2009-03-30 Detection of fibrin and fibrinogen degradation products and associated methods of production and use for the detection and monitoring of cancer

Publications (1)

Publication Number Publication Date
RU2011143747A true RU2011143747A (en) 2013-05-10

Family

ID=41278698

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011143747/15A RU2011143747A (en) 2009-03-30 2009-03-30 DETECTION OF FIBRIN AND FIBRINOGEN DECOMPOSITION PRODUCTS AND RELATED METHODS FOR PRODUCING AND USING FOR DETECTING AND MONITORING CANCER

Country Status (9)

Country Link
EP (1) EP2414843A1 (en)
JP (1) JP2012522246A (en)
KR (1) KR20120057562A (en)
CN (1) CN102405413A (en)
AU (1) AU2009343805A1 (en)
BR (1) BRPI0924286A2 (en)
CA (1) CA2755486A1 (en)
RU (1) RU2011143747A (en)
WO (1) WO2010114514A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2742279C2 (en) * 2016-02-22 2021-02-04 ЭлЭсАй МЕДИЕНС КОРПОРЕЙШН Reagent for evaluating cross-crosslinked fibrin splitting product and method of such evaluation

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012145399A2 (en) * 2011-04-20 2012-10-26 Traxxsson, Llc Methods of diagnosing cancer in a patient
US20140350129A1 (en) 2011-09-07 2014-11-27 Genway Biotech, Inc. Diagnostic assay to predict cardiovascular risk
US20160146834A1 (en) 2013-07-12 2016-05-26 Emory University Diagnostic assay to predict cardiovascular risk
CN103954758A (en) * 2014-05-15 2014-07-30 海南世济医学技术有限公司 Detection method and kit for fibrous proteins and fibrinogen and degradation products thereof
CN104062436B (en) * 2014-06-06 2016-02-10 上海良润生物医药科技有限公司 FXYD is in preparation diagnosis and indicate the application in lung cancer marker and FXYD double crush syndrome detection kit
GB201518466D0 (en) * 2015-10-19 2015-12-02 Cizzle Biotechnology Ltd Use
JP6667380B2 (en) * 2016-06-17 2020-03-18 シスメックス株式会社 Method for blood analysis, blood analyzer, computer program, calibrator set, and method for producing calibrator set
CN106680482A (en) * 2016-12-23 2017-05-17 上海良润生物医药科技有限公司 Urine FXYD detection kit
TW202313954A (en) * 2021-09-28 2023-04-01 華宇藥品股份有限公司 Method of biomarker detection in companion animals

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1019727A1 (en) * 1997-06-03 2000-07-19 Amdl, Inc Immunoassay for the detection of cancer
US20040033544A1 (en) * 2000-03-07 2004-02-19 Ngo That T. Polyclonal antibodies against fibrinogen degradation products and associated methods of production and use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2742279C2 (en) * 2016-02-22 2021-02-04 ЭлЭсАй МЕДИЕНС КОРПОРЕЙШН Reagent for evaluating cross-crosslinked fibrin splitting product and method of such evaluation

Also Published As

Publication number Publication date
CA2755486A1 (en) 2010-10-07
CN102405413A (en) 2012-04-04
JP2012522246A (en) 2012-09-20
WO2010114514A1 (en) 2010-10-07
KR20120057562A (en) 2012-06-05
EP2414843A1 (en) 2012-02-08
BRPI0924286A2 (en) 2016-01-26
AU2009343805A1 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
RU2011143747A (en) DETECTION OF FIBRIN AND FIBRINOGEN DECOMPOSITION PRODUCTS AND RELATED METHODS FOR PRODUCING AND USING FOR DETECTING AND MONITORING CANCER
Wolff et al. Monitoring antibody response following SARS-CoV-2 infection: diagnostic efficiency of 4 automated immunoassays
Leligdowicz et al. Validation of two multiplex platforms to quantify circulating markers of inflammation and endothelial injury in severe infection
Zhang et al. Multiplex quantitative detection of SARS-CoV-2 specific IgG and IgM antibodies based on DNA-assisted nanopore sensing
MX2007014815A (en) Improved immunoassay methods.
WO2013132347A3 (en) Improved elisa immunoassay for calprotectin
Hasanzadeh et al. Optical immunosensing of effective cardiac biomarkers on acute myocardial infarction
Salimi-Moosavi et al. Rapid affinity measurement of protein–protein interactions in a microfluidic platform
Real-Fernández et al. Label-free method for anti-glucopeptide antibody detection in Multiple Sclerosis
WO2008063663A3 (en) Poly (ethylene glycol) anti-body detection assays and kits for performing thereof
RU2013158667A (en) METHOD FOR DIAGNOSTIC OF GACHET DISEASE
NO20062280L (en) Test
Bardin et al. Does the anti-prothrombin antibodies measurement provide additional information in patients with thrombosis?
CN109313195A (en) For providing the method for cancer of bile ducts diagnostic message and for the device of Diagnosing Biliary Tract Carcinoma cancer
CN103874925B (en) Method according to latex agglutination detection Transin-1
JP2020526745A5 (en)
FI20012603A0 (en) Diagnostic method
RU2008130888A (en) MAS-2VR AS A MARKER FOR DIAGNOSTICS OF STOMACH CANCER
Noubouossié et al. An automated chemiluminescence immunoassay may detect mostly relevant IgG anticardiolipin antibodies according to revised Sydney criteria
DE602005010548D1 (en) IMPROVED METHOD FOR DIAGNOSIS OF ACUTE CORONARY SYNDROME
CY1109461T1 (en) IMPROVED IMMUNOLOGICAL DETERMINATION METHODS
Sharma et al. Limited utility of a rapid quantitative enzyme-linked fluorescent assay for the D-dimer in the diagnosis of overt disseminated intravascular coagulation
WO2014159920A4 (en) A device and method for the detection and diagnosis of aggressive and metastatic cancer and cancer stem cells employing podocalyxin and tra biomarkers
JP2019525175A5 (en)
Kim et al. Hyper sensitive strip test with chemi-luminescence signal band

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20130517